TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort - PubMed (original) (raw)
. 2007 Jul 5;26(31):4596-9.
doi: 10.1038/sj.onc.1210237. Epub 2007 Jan 22.
K Fall, S Perner, O Andrén, F Schmidt, S R Setlur, Y Hoshida, J-M Mosquera, Y Pawitan, C Lee, H-O Adami, L A Mucci, P W Kantoff, S-O Andersson, A M Chinnaiyan, J-E Johansson, M A Rubin
Affiliations
- PMID: 17237811
- DOI: 10.1038/sj.onc.1210237
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
F Demichelis et al. Oncogene. 2007.
Erratum in
- Oncogene. 2007 Aug 16;26(38):5692
Abstract
The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.
Similar articles
- Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J. Hofer MD, et al. Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008. Cancer Res. 2009. PMID: 19147579 - Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M, Lissbrant E, Damber JE, Stenman G. Winnes M, et al. Oncol Rep. 2007 May;17(5):1033-6. Oncol Rep. 2007. PMID: 17390040 - Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA. Rubio-Briones J, et al. J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19. J Urol. 2010. PMID: 20303538 - Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB. Shah RB. Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review. - [Molecular biology and prostate cancer: evolution or revolution?].
Molinié V, Beuzeboc P, Mahjoub WK; Les membres du sous-comité prostate du Comité de cancérologie de l'Association française d'urologie. Molinié V, et al. Ann Pathol. 2008 Oct;28(5):354-62. doi: 10.1016/j.annpat.2008.07.004. Epub 2008 Oct 9. Ann Pathol. 2008. PMID: 19068390 Review. French.
Cited by
- TMPRSS2::ETS translocation in nonprostatic malignancies: an unexpected finding in thymic carcinoma and pulmonary adenocarcinoma.
Németh K, Báthory-Fülöp L, Kohánka A, Simon A, Tóth E, Melegh Z. Németh K, et al. Virchows Arch. 2024 Sep 16. doi: 10.1007/s00428-024-03927-0. Online ahead of print. Virchows Arch. 2024. PMID: 39283524 No abstract available. - Prostate cancer biomarkers: from early diagnosis to precision treatment.
Dahiya V, Hans S, Kumari R, Bagchi G. Dahiya V, et al. Clin Transl Oncol. 2024 Oct;26(10):2444-2456. doi: 10.1007/s12094-024-03508-2. Epub 2024 May 14. Clin Transl Oncol. 2024. PMID: 38744755 Review. - Molecular complexity of intraductal carcinoma of the prostate.
Zhu S, Xu N, Zeng H. Zhu S, et al. Cancer Med. 2024 Jan;13(2):e6939. doi: 10.1002/cam4.6939. Cancer Med. 2024. PMID: 38379333 Free PMC article. Review. - The yin and yang of chromosomal instability in prostate cancer.
Carceles-Cordon M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V. Carceles-Cordon M, et al. Nat Rev Urol. 2024 Jun;21(6):357-372. doi: 10.1038/s41585-023-00845-9. Epub 2024 Feb 2. Nat Rev Urol. 2024. PMID: 38307951 Review. - Identification of novel somatic fusions of ERG-VEGFA, TMPRSS2-ERG, and VEGFA-TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report.
Liu Q, Wang S, Wang Z, Tang P, Zhang D, Lan W, Jiang J. Liu Q, et al. Cancer Innov. 2022 Jun 9;1(1):114-118. doi: 10.1002/cai2.11. eCollection 2022 Jun. Cancer Innov. 2022. PMID: 38089454 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical